申请人:NANJING TRANSTHERA BIOSCIENCES CO. LTD.
公开号:US20200361919A1
公开(公告)日:2020-11-19
The present invention belongs to the technical field of medicine, and particularly relates to a compound represented by Formula I, a pharmaceutically acceptable salt thereof, and a stereoisomer thereof, R
4
, R
4
′, R
5
, R
5
′, R
6
, R
7
, R
1a
, R
2a
, m, n, t
1
, and t
2
are as defined in the description; the present invention further relates to a Crystalline Form of the compound represented by Formula I, and the present invention also relates to a pharmaceutical preparation, a pharmaceutical composition, a preparation method of these compounds and Crystalline Forms thereof, as well as a use thereof in manufacture of a medicament for treating a related disease mediated by abnormality of indoleamine 2,3-dioxygenase (IDO).
本发明属于医学技术领域,特别涉及一种由化学式I表示的化合物,其药学上可接受的盐,及其立体异构体,其中R4、R4'、R5、R5'、R6、R7、R1a、R2a、m、n、t1和t2如描述中所定义;本发明还涉及化学式I表示的化合物的晶体形式,本发明还涉及一种制药制剂、一种制药组合物、这些化合物及其晶体形式的制备方法,以及其在制造用于治疗由吲哚胺2,3-二氧化酶(IDO)异常介导的相关疾病的药物中的用途。